561 – 570 of 7628
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1
(
- Contribution to journal › Article
-
Mark
Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer
(
- Contribution to journal › Article
-
Mark
Striving to excel–effects from vacation periods on cancer incidence and outcome
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
(
- Contribution to journal › Article
-
Mark
High-Throughput Drug Screening Revealed That Ciclopirox Olamine Can Engender Gastric Cancer Stem-like Cells
(
- Contribution to journal › Article
-
Mark
Initial pathology in aggressive pituitary tumours and carcinomas : 2b or not 2b?-that is the question
(
- Contribution to journal › Article
-
Mark
ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)
(
- Contribution to journal › Article
-
Mark
Evidence for distinct mechanisms of immune suppression in EBV-positive and EBV-negative Hodgkin lymphoma
(
- Contribution to journal › Article
-
Mark
A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: Application to BRCA1 and BRCA2
(
- Contribution to journal › Article
-
Mark
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma with Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
(
- Contribution to journal › Article